BT-5528

N/A

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug NameBT-5528
Drug Alias NameBT5528BT-5528
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionEphrin type-A receptor 2 antagonists
TargetsEphrin type-A receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBicycle Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBicycle Tx Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A